Why Crashing Your E2 With Anastrozole Is Wrecking Your TRT Results

Watch the full video on Rumble: https://rumble.com/v7fgjta-why-crashing-your-e2-with-anastrozole-is-wrecking-your-trt-results.html

Estradiol Is Not the Enemy on TRT: What Anastrozole Actually Costs You

You go in for bloodwork three months into TRT, and your doctor's going to say, well, your estrogen is high. Then comes the anastrozole prescription, and the number on the next lab drops, and everyone feels like the problem got solved.

The number moved, but the problem did not, and that gap between the two is where most men on TRT get led astray.

Here is the chain, start to finish, so you can see where the mistake sits. You inject testosterone, and some of that testosterone gets converted into estradiol by an enzyme called aromatase, which lives in fat tissue, and the more fat tissue you carry, the more conversion capacity you have. So a heavier guy on the same dose ends up with more estradiol than a leaner guy on the same dose, and the estradiol reading on his lab is telling you something true about his body composition, not something wrong about his hormones.

Anastrozole blocks aromatase, but it does not address why aromatase activity was elevated in the first place.

And now what we've done is we've created this cycle where we're creating more of the problem that we could have solved by not being fat and then treating that problem with more drugs that are going to create even more long-term problems for you, specifically affecting bone density, cardiovascular health, prostate health, brain function, sleep quality, performance, strength, et cetera.

Bone is the part of that list with the clearest data behind it. Burnett-Bowie and colleagues gave older men with low testosterone one milligram of anastrozole daily for twelve months, and while testosterone went up as expected, spine bone mineral density went down compared to placebo, and markers of bone breakdown went up (Burnett-Bowie et al., 2009). So testosterone rose, and bone got worse anyway, which tells you estradiol was doing the structural work.

Estradiol acts on receptors in regions of the brain handling memory and glucose metabolism, and work on estrogen loss and brain aging describes exactly this kind of decline when estradiol signaling drops off (Jett et al., 2022). Most of that research is in women, so I cannot point you to a study showing the same in men on anastrozole.

Prostate function, sleep quality, strength, and athletic output round out the list. I have seen all four move in the wrong direction when a client crashes estradiol, and the joint pain usually shows up first, but the research hasn't answered these in men on TRT the way it has answered bone.

Show me a guy on TRT who feels good and feels healthy and performs well, and I will show you labs with elevated E2.

That is a pattern, not a trial, since there is no study assigning men on TRT to high versus normal estradiol and measuring how they feel. Treat it as something I have watched across a lot of bloodwork rather than a settled finding.

In fact, I want my E2 to be as high as I can possibly get it without experiencing the side effects. The ceiling is symptoms, not a reference range, and those symptoms come down to a short list: water retention, nipple sensitivity, and mood swings. If none of those are present, a sensitive estradiol of sixty or seventy is not an emergency, and the number alone is not a reason to medicate.

So the first move is not a drug. Drop body fat, and aromatase capacity drops with it, and the estradiol number comes down on its own without touching the hormone your bones and brain are running on.

Dose and frequency come next. Lower total weekly testosterone means less substrate to convert, and splitting the dose into smaller, more frequent injections flattens the peaks that drive conversion hardest.

If you have real symptoms after all that, a low dose of an aromatase inhibitor, titrated slowly and rechecked, has a place, though the milligram-a-day protocols doctors default to do not belong anywhere near that plan.

Research: Burnett-Bowie et al., J Clin Endocrinol Metab, 2009; Jett et al., Front Aging Neurosci, 2022.

References:

Burnett-Bowie SA, McKay EA, Lee H et al.. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009. https://pubmed.ncbi.nlm.nih.gov/19820017/

Guth MA. Compounded Testosterone Troches TO OPTIMIZE HEALTH AND THE TESTOSTERONE CONTROVERSY. Int J Pharm Compd. 2015. https://pubmed.ncbi.nlm.nih.gov/26714360/

Jett S, Schelbaum E, Jang G et al.. Ovarian steroid hormones: A long overlooked but critical contributor to brain aging and Alzheimer's disease. Front Aging Neurosci. 2022. https://pubmed.ncbi.nlm.nih.gov/35928995/